Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.61 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.61 |
| ▸ | VEGFA | P15692 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30831070 | 0.88 | DDB1 (0.60) | CRBNDDB1 | |
| SCHEMBL30304647 | 0.85 | DDB1 (0.66) | CRBNDDB1VEGFAEGLN1 | |
| SCHEMBL26641333 | 0.85 | CRBN (0.60) | CRBNDDB1GPR119 | |
| SCHEMBL21876964 | 0.84 | DDB1 (0.67) | CRBNDDB1GPR119 | |
| SCHEMBL31232880 | 0.84 | CRBN (0.64) | CRBNDDB1POLB | |
| SCHEMBL23301226 | 0.84 | DDB1 (0.67) | CRBNDDB1GPR119 | |
| SCHEMBL30643707 | 0.84 | CRBN (0.59) | CRBNDDB1GSPT1POLB | |
| SCHEMBL23301622 | 0.84 | CRBN (0.67) | CRBNDDB1GPR119POLB | |
| SCHEMBL25187964 | 0.84 | CRBN (0.67) | CRBNDDB1GPR119POLB | |
| SCHEMBL24206650 | 0.84 | CRBN (0.67) | CRBNDDB1GPR119POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |